Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Identifieur interne : 002455 ( Ncbi/Checkpoint ); précédent : 002454; suivant : 002456Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
Auteurs : Robert A. Hauser [États-Unis] ; Mark F. Lew ; Howard I. Hurtig ; William G. Ondo ; Joanne Wojcieszek ; Cheryl J. Fitzer-AttasSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (therapeutic use), Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Indans (administration & dosage), Levodopa (therapeutic use), Longitudinal Studies, Male, Middle Aged, Monoamine Oxidase Inhibitors (administration & dosage), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Parkinson Disease (psychology), Quality of Life, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
- MESH :
- chemical , administration & dosage : Indans, Monoamine Oxidase Inhibitors.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- drug therapy : Parkinson Disease.
- physiopathology : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Humans, Longitudinal Studies, Male, Middle Aged, Quality of Life, Reproducibility of Results, Retrospective Studies, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
The purpose of this study to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (+/-SD) duration in the study was 3.6 +/- 2.1 years; 177 subjects received rasagiline for > or =5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.
DOI: 10.1002/mds.22402
PubMed: 19086083
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001F10
- to stream PubMed, to step Curation: 001F10
- to stream PubMed, to step Checkpoint: 001D33
- to stream Ncbi, to step Merge: 002455
- to stream Ncbi, to step Curation: 002455
Links to Exploration step
pubmed:19086083Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><nlm:affiliation>Parkinsons's Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA. rhauser@health.usf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F" last="Lew">Mark F. Lew</name></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I" last="Hurtig">Howard I. Hurtig</name></author><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name></author><author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22402</idno><idno type="RBID">pubmed:19086083</idno><idno type="pmid">19086083</idno><idno type="wicri:Area/PubMed/Corpus">001F10</idno><idno type="wicri:Area/PubMed/Curation">001F10</idno><idno type="wicri:Area/PubMed/Checkpoint">001D33</idno><idno type="wicri:Area/Ncbi/Merge">002455</idno><idno type="wicri:Area/Ncbi/Curation">002455</idno><idno type="wicri:Area/Ncbi/Checkpoint">002455</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><nlm:affiliation>Parkinsons's Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606, USA. rhauser@health.usf.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinsons's Disease and Movement Disorders Center, University of South Florida, 5 Tampa General Circle, Tampa, FL 33606</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F" last="Lew">Mark F. Lew</name></author><author><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I" last="Hurtig">Howard I. Hurtig</name></author><author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name></author><author><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name></author><author><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Indans (administration & dosage)</term><term>Levodopa (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (administration & dosage)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (psychology)</term><term>Quality of Life</term><term>Reproducibility of Results</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Indans</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Quality of Life</term><term>Reproducibility of Results</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study to compare the long-term clinical outcome of early versus delayed rasagiline treatment in early Parkinson's disease (PD). Subjects (N = 404) were randomly assigned to initial treatment with rasagiline (early-start group) or placebo for 6 months followed by rasagiline (delayed-start group) in the TEMPO study. Subjects who chose to participate in an open-label extension (N = 306) continued to receive rasagiline as well as other PD medications as needed. Average (+/-SD) duration in the study was 3.6 +/- 2.1 years; 177 subjects received rasagiline for > or =5.0 years. Over the entire 6.5-year follow-up period, the adjusted mean difference in change from baseline in total UPDRS scores was 2.5 units (SE 1.1; P = 0.021) or 16% (SE 5.7; P = 0.006) in favor of the early-start versus delayed-start rasagiline group. Although the interaction between treatment and time was significant, values for the early-start group were better than the delayed-start group across all time points. Significantly less worsening (percent change) in total UPDRS scores was observed in the early-start group at the time points 0.5, 1.5, 2.0, 3.0, 4.5, 5.0, and 5.5 years (P < 0.05). Compared to delayed start, early initiation of rasagiline provided long-term clinical benefit, even in the face of treatment with other dopaminergic agents. This might reflect enduring benefits due to neuroprotection or effects on compensatory mechanisms in early PD.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><noCountry><name sortKey="Fitzer Attas, Cheryl J" sort="Fitzer Attas, Cheryl J" uniqKey="Fitzer Attas C" first="Cheryl J" last="Fitzer-Attas">Cheryl J. Fitzer-Attas</name><name sortKey="Hurtig, Howard I" sort="Hurtig, Howard I" uniqKey="Hurtig H" first="Howard I" last="Hurtig">Howard I. Hurtig</name><name sortKey="Lew, Mark F" sort="Lew, Mark F" uniqKey="Lew M" first="Mark F" last="Lew">Mark F. Lew</name><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G" last="Ondo">William G. Ondo</name><name sortKey="Wojcieszek, Joanne" sort="Wojcieszek, Joanne" uniqKey="Wojcieszek J" first="Joanne" last="Wojcieszek">Joanne Wojcieszek</name></noCountry><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002455 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002455 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:19086083
|texte= Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:19086083" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |